ProPharmace
Training Through Innovation

For FILGRASTIM

Monitoring of patient parameters

Regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).

Directions for administration

With intravenous use or subcutaneous use

For *subcutaneous* or *intravenous infusion*, manufacturer advises give continuously *or* intermittently *in* Glucose 5%; for a filgrastim concentration of less than 1500000 units/mL (15 micrograms/mL) albumin solution (human albumin solution) is added to produce a final albumin concentration of 2 mg/mL; should not be diluted to a filgrastim concentration of less than 200000 units/mL (2 micrograms/mL) and should not be diluted with sodium chloride solution.

Prescribing and dispensing information

Filgrastim is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see *Biological medicines* and *Biosimilar medicines*, under Guidance on prescribing.

1 million units of filgrastim solution for injection contains 10 micrograms filgrastim.